Immuntherapie beim Lungenkarzinom

Zusammenfassung

Monoklonale Antikörper gegen den PD-1-Rezeptor oder seine Liganden sollen zur Wiederherstellung einer T-Zell-Antwort gegen Tumorantigene führen. Dieses immunologische Wirkprinzip ist mit dem Anti-PD-1-Antikörper Nivolumab kürzlich für die Therapie des Lungenkarzinoms zugelassen worden. Eine Gruppe von „Langzeitrespondern“ sowie ein insgesamt moderates Toxizitätsprofi machen diesen Therapieansatz besonders interessant.

Abstract

Monoclonal antibodies against the PD-1 receptor or its ligands result in a recovery of T cell responses against tumor antigens. Nivolumab is the first antibody that has been approved in lung cancer. This mode of action is very intersting, especially because of long term responses and the moderate toxicity.

Schlüsselwörter

Lungenkarzinom - Checkpoint-Inhibitoren - Immuntherapie - PD-1 - Nivolumab

Keywords

NSCLC - checkpoint inhibitors - immunotherapy - PD-1 - Nivolumab

^* T. W. und B. W. teilen sich die Erstautorenschaft

• Literatur

• 1 Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432-1433
• 2 Spigel DR, Reckamp KL, Rizvi NA et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1) vs. docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer. J Clin Oncol 2015; 33 (suppl) abstract 8009
• 3 Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
• 4 Reckamp K, Spigel DR, Rizvi NA et al. Phase 3, global, randomized trial (CheckMate 017) of Nivolumab vs Docetaxel in advanced squamous (SQ) cell non-small cell lung cancer (NSCLC). 16th World Conference of Lung Cancer, 07. September 2015 Denver, USA: Abstract verfügbar auf http://library.iaslc.org/
• 5 Hellmann MD, Creelan BC, Woo K et al. Smoking history and response to Nivolumab in patients with advanced NSCLCS. Ann Oncol 2014; 25 (Suppl. 04) iv429
• 6 Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128
• 7 Paz-Ares L, Horn L, Borghaei H et al. Phase III, randomized trial (Check-Mate 057) of nivolumab versus docetaxel in advanced non-squamous cell non-small cell lung cancer. J Clin Oncol 2015; 33 (suppl, abstr LBA109)
• 8 Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
• 9 Garon EB, Rizvi NA et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028
• 10 Spira AL, Park K et al. Efficacy, safety, and predictive biomarker results from a randomized phase II study comparing MPDL3280A versus Docetaxel in 2L/3L (POPLAR). J Clin Oncol 2015; 33 (suppl; abstr 8010)
• 11 Carbognin L, Pilotto S et al. Differential activity of Nivolumab, Pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015; 10 (06) e0130142